Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide for transfusion- or iron-dependent anemia due to gastrointestinal angiodysplasia
NL-OMON44271Phase 3Active, not recruiting
- Sponsor
- Maag Lever Darm Stichting
- Start
- Sep 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of octreotide in angiodysplasia, refractory anemia (RA), sponsored by Maag Lever Darm Stichting. Started Sep 2015; status: active, not recruiting.
02
Drugs
octreotide
03
Conditions
angiodysplasiarefractory anemia (RA)
Beyond the preview
Go deeper on NL-OMON44271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44271.